Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Teriflunomide.
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis (MS). Teriflunomide has demonstrated clinical efficacy and safety in a number of large, multicenter, phase III clinical trials and is an attractive agent to add to the growing repertoire of available treatments for MS, as it has the benefit of oral administration.
Teriflunomide is thought to work by decreasing certain immune system cells (lymphocytes) which can attack the nerves in human brain and spinal cord. This helps decrease the number of flare-ups (relapses) and may help slow down physical problems caused by MS.
This certificate is 25th CEP issued by EDQM to Shilpa, which showcases our continued expertise and commitment to develop, manufacture and supply of quality oriented products of global standards.
Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 814.70 as compared to the previous close of Rs. 800.80. The total number of shares traded during the day was 9550 in over 794 trades.
The stock hit an intraday high of Rs. 821.85 and intraday low of 792.75. The net turnover during the day was Rs. 7740839.00. |